su011248
Unresectable or Metastatic Colorectal Cancer
PfizerPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Unresectable or Metastatic Colorectal Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM Shanghai EpimAb Biotherapeutics Co., Ltd. | Phase 4 | BBB |
Levoleucovorin China Medical University, China | Phase 2 | B |
Same molecule, other indications
su011248 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →